Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Tornado will enhance Bruker’s biopharma PAT portfolio with its well-established products
Almost 300 million people globally have chronic hepatitis B
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Agreement provides customers in the majority of Europe* access to supply through Univar Solutions distribution network
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
